AHS 2022 | The promise of pharmacogenomics in migraine

Yi-Chieh Chen, PharmD, Mayo Clinic, Rochester, MN, discusses the current status and challenges concerning pharmacogenomic phenotypes in migraine. Based on the experience with antidepressants, there are prospects in utilizing pharmacogenomic phenotypes to help predict dosing in migraine preventive treatments. However, as this is not common in headache care, there are limitations in the current sample sizes, requiring larger studies to comprehensively investigate the migraine population. A prospective study designed to capture this target population would greatly help mitigate the current challenges. Furthermore, there is a need for more existing pharmacogenomic reports on migraine preventive treatments to be able to conduct these studies. This interview took place during the 2022 American Headache Society (AHS) Meeting in Denver, CO.